The identification of LRP8 as a critical regulator of ferroptosis sensitivity is consistent with data from the cancer therapeutic response portal (CTRP), showing that LRP8 expression strongly correlates with resistance to GPX4 inhibitors (ML210, RSL3, and ML162; Appendix Fig S2A; Basu et al, 2013). The gene discussed is GPX4; the disease is cancer.